Insilico Medicine vs Recursion, according to AI

“Bottom line: If you told me *“We are a 20–100 person biotech, have proprietary disease datasets, and want 5–20 novel targets to drive our next pipeline,”* I'd start with Insilico, run a serious bake-off against Recursion, and potentially add BenevolentAI as a complementary knowledge/hypothesis layer.”